Clinical and biologic characteristics of the population of 96 MDS patients
| Characteristic . | All . | TET2 mutated . | TET2 unmutated . | P . |
|---|---|---|---|---|
| Demographics | ||||
| n (%) | 96 (100) | 22 (22.9) | 74 (77.1) | |
| Median age (IQR*) | 71.5 (63.5-79) | 70.5 (61-75) | 72 (64-77) | .306 |
| Sex ratio, M/F | 1.5 | 2.3 | 1.3 | .459 |
| ATCD chemotherapy or radiotherapy, yes/no (%) | 23/57 (28.7) | 5/13 (27.8) | 18/44 (29.0) | .671 |
| FAB classification, n (%) | .803 | |||
| RA | 29 (30.2) | 6 (27.3) | 23 (31.1) | |
| RARS | 12 (12.5) | 2 (9.1) | 10 (13.5) | |
| RAEB | 47 (49.0) | 13 (59.1) | 34 (45.9) | |
| RAEBt | 8 (8.3) | 1 (4.5) | 7 (9.5) | |
| WHO classification, n (%) | .909 | |||
| RA | 16 (16.7) | 4 (18.2) | 12 (16.2) | |
| 5q− syndrome | 2 (2.1) | 0 (0.0) | 2 (2.7) | |
| MDS-U | 4 (4.2) | 1 (4.5) | 3 (4.1) | |
| RCMD | 7 (7.3) | 1 (4.5) | 6 (8.1) | |
| RARS/RCMD-RS/RARS-T | 12 (12.5) | 2 (9.1) | 10 (13.5) | |
| RAEB1 | 25 (26.0) | 8 (36.5) | 17 (23.0) | |
| RAEB2 | 23 (23.9) | 5 (22.7) | 18 (24.3) | |
| sAML | 7 (7.3) | 1 (4.5) | 6 (8.1) | |
| Peripheral blood, median (IQR*) | ||||
| Hb, g/dL | 9.4 (8.6-10.9) | 9.4 (8.6-10.4) | 9.4 (8.6-10.4) | .322 |
| MCV, fL | 99 (90-104) | 99 (89-11.8) | 98 (90-105) | .658 |
| Leukocytes, g/L | 3.9 (2.8-6.3) | 5.0 (2.6-6.3) | 3.8 (2.8-6.3) | .654 |
| Neutrophils, g/L | 1.8 (1.0-3.9) | 2.3 (0.8-3.7) | 1.8 (1.0-4.0) | .872 |
| Platelets, g/L | 164 (85-248) | 178 (92-247) | 156 (80-250) | .845 |
| Reticulocytes, g/L | 58 (35-76) | 58 (40-63) | 58 (27-88) | .431 |
| Bone marrow | ||||
| Blasts, median % (IQR*) | 6 (3-11) | 6 (3-10) | 5 (3-11) | .751 |
| Multilineage dysplasia, yes/no (%) | 58/27 (68.2) | 13/7 (65.0) | 45/20 (70.2) | .786 |
| Karyotype, n (%) | > .999 | |||
| Favorable | 63 (65.6) | 16 (72.7) | 48 (64.9) | |
| Intermediate | 20 (20.8) | 4 (18.2) | 16 (21.6) | |
| Unfavorable | 13 (13.5) | 3 (13.6) | 10 (13.5) | |
| IPSS, n (%) | .761 | |||
| Low | 31 (32.3) | 7 (31.8) | 24 (32.4) | |
| Int-1 | 30 (31.2) | 8 (36.4) | 22 (29.7) | |
| Int-2 | 24 (25.0) | 6 (27.3) | 18 (24.3) | |
| High | 11 (11.5) | 1 (4.5) | 10 (13.5) | |
| Treatments, n (%) | ||||
| None | 40 (41.7) | 9 (40.9) | 31 (41.9) | .792 |
| Red blood cell transfusions | 26 (27.1) | 6 (27.3) | 20 (27.0) | > .999 |
| Erythropoiesis-stimulating agent with or without G-CSF | 33 (34.4) | 7 (31.8) | 26 (35.1) | .812 |
| Lenalidomide/thalidomide | 5 (5.2) | 1 (4.5) | 4 (5.4) | .901 |
| Demethylating agents | 5 (5.2) | 1 (4.5) | 4 (5.4) | .901 |
| Low doses or intensive chemotherapy | 7 (7.3) | 2 (9.1) | 5 (6.8) | .625 |
| Characteristic . | All . | TET2 mutated . | TET2 unmutated . | P . |
|---|---|---|---|---|
| Demographics | ||||
| n (%) | 96 (100) | 22 (22.9) | 74 (77.1) | |
| Median age (IQR*) | 71.5 (63.5-79) | 70.5 (61-75) | 72 (64-77) | .306 |
| Sex ratio, M/F | 1.5 | 2.3 | 1.3 | .459 |
| ATCD chemotherapy or radiotherapy, yes/no (%) | 23/57 (28.7) | 5/13 (27.8) | 18/44 (29.0) | .671 |
| FAB classification, n (%) | .803 | |||
| RA | 29 (30.2) | 6 (27.3) | 23 (31.1) | |
| RARS | 12 (12.5) | 2 (9.1) | 10 (13.5) | |
| RAEB | 47 (49.0) | 13 (59.1) | 34 (45.9) | |
| RAEBt | 8 (8.3) | 1 (4.5) | 7 (9.5) | |
| WHO classification, n (%) | .909 | |||
| RA | 16 (16.7) | 4 (18.2) | 12 (16.2) | |
| 5q− syndrome | 2 (2.1) | 0 (0.0) | 2 (2.7) | |
| MDS-U | 4 (4.2) | 1 (4.5) | 3 (4.1) | |
| RCMD | 7 (7.3) | 1 (4.5) | 6 (8.1) | |
| RARS/RCMD-RS/RARS-T | 12 (12.5) | 2 (9.1) | 10 (13.5) | |
| RAEB1 | 25 (26.0) | 8 (36.5) | 17 (23.0) | |
| RAEB2 | 23 (23.9) | 5 (22.7) | 18 (24.3) | |
| sAML | 7 (7.3) | 1 (4.5) | 6 (8.1) | |
| Peripheral blood, median (IQR*) | ||||
| Hb, g/dL | 9.4 (8.6-10.9) | 9.4 (8.6-10.4) | 9.4 (8.6-10.4) | .322 |
| MCV, fL | 99 (90-104) | 99 (89-11.8) | 98 (90-105) | .658 |
| Leukocytes, g/L | 3.9 (2.8-6.3) | 5.0 (2.6-6.3) | 3.8 (2.8-6.3) | .654 |
| Neutrophils, g/L | 1.8 (1.0-3.9) | 2.3 (0.8-3.7) | 1.8 (1.0-4.0) | .872 |
| Platelets, g/L | 164 (85-248) | 178 (92-247) | 156 (80-250) | .845 |
| Reticulocytes, g/L | 58 (35-76) | 58 (40-63) | 58 (27-88) | .431 |
| Bone marrow | ||||
| Blasts, median % (IQR*) | 6 (3-11) | 6 (3-10) | 5 (3-11) | .751 |
| Multilineage dysplasia, yes/no (%) | 58/27 (68.2) | 13/7 (65.0) | 45/20 (70.2) | .786 |
| Karyotype, n (%) | > .999 | |||
| Favorable | 63 (65.6) | 16 (72.7) | 48 (64.9) | |
| Intermediate | 20 (20.8) | 4 (18.2) | 16 (21.6) | |
| Unfavorable | 13 (13.5) | 3 (13.6) | 10 (13.5) | |
| IPSS, n (%) | .761 | |||
| Low | 31 (32.3) | 7 (31.8) | 24 (32.4) | |
| Int-1 | 30 (31.2) | 8 (36.4) | 22 (29.7) | |
| Int-2 | 24 (25.0) | 6 (27.3) | 18 (24.3) | |
| High | 11 (11.5) | 1 (4.5) | 10 (13.5) | |
| Treatments, n (%) | ||||
| None | 40 (41.7) | 9 (40.9) | 31 (41.9) | .792 |
| Red blood cell transfusions | 26 (27.1) | 6 (27.3) | 20 (27.0) | > .999 |
| Erythropoiesis-stimulating agent with or without G-CSF | 33 (34.4) | 7 (31.8) | 26 (35.1) | .812 |
| Lenalidomide/thalidomide | 5 (5.2) | 1 (4.5) | 4 (5.4) | .901 |
| Demethylating agents | 5 (5.2) | 1 (4.5) | 4 (5.4) | .901 |
| Low doses or intensive chemotherapy | 7 (7.3) | 2 (9.1) | 5 (6.8) | .625 |
Comparison between categorical variables was performed by χ2 or Fisher exact tests. Comparison between continuous variables was performed by use of the univariate Wilcoxon test.
ATCD indicates antecedent; G-CSF, granulocyte colony-stimulating factor; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndromes; MCV, mean corpuscular volume; and sAML, secondary acute myeloid leukemia. Other abbreviations as in Table 1.
IQR indicates Interquartile Range (25%-75%).